BSE: NATCOPHARM - NATCO Pharma Limited

Rentabilité sur six mois: -39.84%
Rendement en dividendes: +0.75%

Calendrier des promotions NATCO Pharma Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise NATCO Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care.

plus de détails
The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

ISIN INE987B01026
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.9395
Дивиденд ао 6
Сайт https://www.natcopharma.co.in
Цена ао 821.35
Changement de prix par jour: +0.767% (821.35)
Changement de prix par semaine: +1.76% (813.35)
Changement de prix par mois: +6.75% (775.35)
Changement de prix sur 3 mois: -31.97% (1216.65)
Changement de prix sur six mois: -39.84% (1375.7)
Changement de prix par an: -16.34% (989.3)
Evolution du prix sur 3 ans: +18.18% (700.35)
Evolution du prix sur 5 ans: +46.38% (565.4)
Evolution des prix depuis le début de l'année: -40.83% (1398.7)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 4.28 4
P/BV 2.91 6
P/E 12.27 8
EV/EBITDA 9.66 8
Total: 7.38

Efficacité

Nom Signification Grade
ROA, % 22.1 7
ROE, % 25.88 8
Total: 6

Dividendes

Nom Signification Grade
Div yield, % 0.7538 1.88
DSI 0.8571 8.57
Total: 2.42

Devoir

Nom Signification Grade
Debt/EBITDA 0.1605 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 110.76 10
Rentabilité Ebitda, % 12.83 2
Rentabilité EPS, % 206.73 10
Total: 8.4
Plus de détails

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Rajeev Nannapaneni CEO & Vice Chairman N/A 1977 (48 années)
Mr. S. V. V. N. Appa Rao Chief Financial Officer N/A
Dr. Donthineni Linga Rao M.D. President of Technical Affairs & Whole Time Director N/A 1952 (73 année)
Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS. MD & Chairman N/A 1945 (80 années)
Mr. Potluri Sivaramakrishna Prasad Executive VP of Corporate Engineering Services & Whole Time Director N/A 1958 (67 années)
Mr. Chekuri Venkat Ramesh C.S. Company Secretary & Compliance Officer 3M
Dr. Pavan Ganapati Bhat Executive VP of Technical Operations & Director N/A 1967 (58 années)
N. Sadasiva Rao Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management N/A
James Rajakumar Vice President of Marketing & Sales - Domestic N/A
Nadella Malleswara Rao VP & Head of Operations

Adresse: India, Hyderabad, Natco House - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.natcopharma.co.in